Treating OSD In 2024 To The Point podcast

Artwork

Indhold leveret af Bryn Mawr Communications (BMC) and Modern Optometry. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Bryn Mawr Communications (BMC) and Modern Optometry eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

To the Point « »
Treating OSD in 2024

8M ago 25:13

Del

MP3•Episode hjem

Indhold leveret af Bryn Mawr Communications (BMC) and Modern Optometry. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Bryn Mawr Communications (BMC) and Modern Optometry eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, kick off 2024 with a conversation about several new and anticipated products for treating ocular surface disease, including cyclosporine ophthalmic solution 0.1% (Vevye, Harrow), perfluorohexyloctane ophthalmic solution (Meibo, Bausch + Lomb), and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals). They also share some practice pearls and professional goals for the year ahead.

… continue reading

50 episoder

Artwork

Treating OSD in 2024

published 8M ago

Del

MP3•Episode hjem

Indhold leveret af Bryn Mawr Communications (BMC) and Modern Optometry. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Bryn Mawr Communications (BMC) and Modern Optometry eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, kick off 2024 with a conversation about several new and anticipated products for treating ocular surface disease, including cyclosporine ophthalmic solution 0.1% (Vevye, Harrow), perfluorohexyloctane ophthalmic solution (Meibo, Bausch + Lomb), and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals). They also share some practice pearls and professional goals for the year ahead.

… continue reading

50 episoder

כל הפרקים

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner